Bosutinib (BOS) as third-line therapy for chronic phase (CP) chronic myeloid leukemia (CML) following failure with imatinib (IM) and dasatinib (DAS) or nilotinib (NIL)

被引：0
|
作者：
Brummendorf, T. H.
Cortes, J. E.
Kantarjian, H.
Gambacorti-Passerini, C.
Baccarani, M.
Kim, D.
Zaritskey, A.
Navarro, J.
Rapoport, A.
Dorlhiac-Llacer, P. E.
Milone, J.
Zanichelli, M.
Besson, N.
Leip, E.
Kelly, V.
Khoury, H. J.
机构：
[1] Rhein Westfal TH Aachen, Univ Klinikum Hamburg Eppendorf, Univ Klinikum Aachen, Aachen, Germany
[2] RWTH, Univ Klinikum Hamburg Eppendorf, Univ Klinikum Aachen, Hamburg, Germany
[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[4] Univ Milano Bicocca, Monza, Italy
[5] Univ Bologna, Bologna, Italy
[6] Seoul St Marys Hosp, Seoul, South Korea
[7] Univ Pavlov, St Petersburg, Russia
[8] Hosp Nacl Edgardo Rebagliati Martins, Lima, Peru
[9] Greenebaum Canc Ctr, Baltimore, MD USA
[10] FMUSP, Hosp Clin, Sao Paulo, Brazil
[11] Inst Trasplante Medula Osea, La Plata, Buenos Aires, Argentina
[12] Univ Sao Paulo, Childrens Inst, Sao Paulo, Brazil
[13] Pfizer Global Res & Dev, Paris, France
[14] Pfizer Inc, Cambridge, MA USA
[15] Emory Univ, Sch Med, Atlanta, GA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.6535
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6535
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Bosutinib (BOS) vs Imatinib (IM) for Newly Diagnosed Chronic Myeloid Leukemia (CML): Initial Results from the BFORE Trial
    Cortes, Jorge
    Gambacorti-Passerini, Carlo
    Deininger, Michael
    Mauro, Michael
    Chuah, Charles
    Kim, Dong Wook
    Reilly, Laurence
    Jeynes-Ellis, Alison
    Leip, Eric
    Bardy-Bouxin, Nathalie
    Hochhaus, Andreas
    Brummendorf, Tim
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S316 - S316
  • [42] Bosutinib (BOS) vs imatinib (IM) for newly diagnosed chronic myeloid leukemia (CML): initial results from the bfore trial
    Bruemmendorf, T. H.
    Gambacorti-Passerini, C.
    Deininger, M.
    Mauro, M. J.
    Chuah, C.
    Kim, D. -W.
    Le Coutre, P.
    Jentsch-Ullrich, K.
    Waller, C.
    Wolf, D.
    Reilly, L.
    Jeynes-Ellis, A.
    Leip, E.
    Bardy-Bouxin, N.
    Hochhaus, A.
    Cortes, J. E.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 121 - 121
  • [43] BOSUTINIB (BOS) VS IMATINIB (IM) FOR NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA (CML): INITIAL RESULTS FROM THE BFORE TRIAL
    Gambacorti-Passerini, C.
    Deininger, M.
    Mauro, M. J.
    Chuah, C.
    Kim, D. -W.
    Reilly, L.
    Jeynes-Ellis, A.
    Leip, E.
    Bardy-Bouxin, N.
    Hochhaus, A.
    Bruemmendorf, T. H.
    Cortes, J. E.
    HAEMATOLOGICA, 2017, 102 : 20 - 20
  • [44] Phase II trial of dasatinib (DAS) in pediatric patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP).
    Gore, Lia
    Kearns, Pamela
    Lee, Maria Lucia
    De Souza, Carmino Antonio
    Bertrand, Yves
    Hijiya, Nobuko
    Stork, Linda C.
    Chung, Nack-Gyun
    Cardenas-Cardos, Rocio
    Saikia, Tapan
    Fagioli, Franca
    Seo, Jong-Jin
    Landman-Parker, Judith
    Lancaster, Donna
    Place, Andrew E.
    Rabin, Karen R.
    Sacchi, Mariana
    Swanink, Rene
    Zwaan, Michel
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [45] SAFETY AND EFFICACY OF SECOND-LINE BOSUTINIB (SKI-606) IN IMATINIB RESISTANT OR INTOLERANT CHRONIC PHASE (CP) CHRONIC MYELOID LEUKEMIA (CML)
    Brummendorf, T.
    Cortes, J.
    Turkina, A.
    Masszi, T.
    Assouline, S.
    Durrant, S.
    Volkert, A.
    Wang, J.
    Arkin, S.
    Gambacorti-Passerini, C.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 468 - 468
  • [46] Nilotinib and Dasatinib in the First-Line Therapy for chronic myeloid Leukemia
    Pretscher, Dominik
    Wilhelm, Martin
    MEDIZINISCHE KLINIK, 2010, 105 (08) : 588 - 588
  • [47] Clinical significance of molecular monitoring in chronic myeloid leukemia (CML) in chronic phase (CP) with imatinib therapy
    Cortes, J
    Talpaz, M
    O'Brien, S
    Jones, D
    Luthra, R
    Garcia-Manero, G
    Giles, F
    Shan, J
    Verstovsek, S
    Rios, MB
    Kantarjian, H
    BLOOD, 2004, 104 (11) : 81A - 81A
  • [48] Bosutinib (BOS) Versus Imatinib for Newly Diagnosed Chronic Phase (CP) Chronic Myeloid Leukemia (CML): Final 5-Year Results from the Bfore Trial
    Brummendorf, Tim H.
    Cortes, Jorge E.
    Milojkovic, Dragana
    Gambacorti-Passerini, Carlo
    Clark, Richard E.
    le Coutre, Philipp D.
    Garcia-Gutierrez, Valentin
    Chuah, Charles
    Kota, Vamsi
    Lipton, Jeffrey H.
    Rousselot, Philippe
    Mauro, Michael J.
    Hochhaus, Andreas
    Monroy, Rafael Hurtado
    Leip, Eric
    Purcell, Simon
    Yver, Anne
    Viqueira, Andrea
    Deininger, Michael W.
    BLOOD, 2020, 136
  • [49] REAL-LIFE COMPARISON OF DASATINIB AND NILOTINIB AS SECOND-LINE THERAPY AFTER IMATINIB FAILURE FOR CHRONIC PHASE CML
    Tiribelli, M.
    Bonifacio, M.
    Binotto, G.
    Iurlo, A.
    Cibien, F.
    Maino, E.
    Guella, A.
    Festini, G.
    Minotto, C.
    De Biasi, E.
    De Marchi, F.
    Scaffidi, L.
    Frison, L.
    Bucelli, C.
    Medeot, M.
    Calistri, E.
    Sancetta, R.
    Stulle, M.
    Krampera, M.
    Gherlinzoni, F.
    Semenzato, G.
    Ambrosetti, A.
    Fanin, R.
    HAEMATOLOGICA, 2016, 101 : 237 - 238
  • [50] COMPARISON OF DASATINIB AND NILOTINIB AS SECOND-LINE THERAPY AFTER INATINIB FAILURE IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS
    Tiribelli, M.
    Bonifacio, M.
    Binotto, G.
    Maino, E.
    Calistri, E.
    De Marchi, F.
    Scaffidi, L.
    Frison, L.
    Medeot, M.
    Ambrosetti, A.
    Semenzato, G.
    Fanin, R.
    HAEMATOLOGICA, 2015, 100 : 132 - 132
12345